{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:55:12Z","timestamp":1781081712141,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10633-021-09825-z","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T04:04:40Z","timestamp":1620273880000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with\u00a0cerliponase alpha: case report"],"prefix":"10.1007","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7369-7887","authenticated-orcid":false,"given":"Florence","family":"Rigaudi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Pichard-Oumlil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Delouvrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lopez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Auvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Delano\u00eb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"9825_CR1","unstructured":"Menache CC., Haenggeli Ch-A., and Safran AB., (2004) Affections du m\u00e9tabolisme g\u00e9n\u00e9ral \u00e0 expression neuro-ophtalmologique., in Neuro-Ophtalmologie - Rapport de la Soci\u00e9t\u00e9 Fran\u00e7aise d'Ophtalmologie, Safran AB., Editor Masson: Paris. p. 425\u2013454"},{"issue":"1","key":"9825_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-018-0300-6","volume":"14","author":"AB Mukherjee","year":"2019","unstructured":"Mukherjee AB et al (2019) Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses. Mol Neurodegener 14(1):4","journal-title":"Mol Neurodegener"},{"key":"9825_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-15720-2","volume-title":"Inborn metabolic diseases. Diagnosis and treatment","author":"JM Saudubray","year":"2012","unstructured":"Saudubray JM, Van den Berghe G, Walters JH (2012) Inborn metabolic diseases. Diagnosis and treatment, 5th edn. Springer-Verlag, Heidelberg","edition":"5"},{"key":"9825_CR4","first-page":"165570","volume":"9","author":"HR Nelvagal","year":"2019","unstructured":"Nelvagal HR et al (2019) Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis 9:165570","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"4","key":"9825_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0883073812448459","volume":"28","author":"MS Perez-Poyato","year":"2013","unstructured":"Perez-Poyato MS et al (2013) Late infantile neuronal ceroid lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol 28(4):470\u2013478","journal-title":"J Child Neurol"},{"issue":"8","key":"9825_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel M et al (2018) Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2(8):582\u2013590","journal-title":"Lancet Child Adolesc Health"},{"key":"9825_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE et al (2017) Management strategies for CLN2 disease. Pediatr Neurol 69:102\u2013112","journal-title":"Pediatr Neurol"},{"issue":"1","key":"9825_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-018-0798-2","volume":"13","author":"N Sima","year":"2018","unstructured":"Sima N et al (2018) Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1\/PPT1) and late infantile (CLN2\/TPP1) neuronal ceroid lipofuscinoses. Orphanet J Rare Dis 13(1):54","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"9825_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","volume":"18","author":"SE Mole","year":"2019","unstructured":"Mole SE et al (2019) Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol 18(1):107\u2013116","journal-title":"Lancet Neurol"},{"issue":"4","key":"9825_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40263-019-00620-8","volume":"33","author":"A Kohlschutter","year":"2019","unstructured":"Kohlschutter A et al (2019) Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs 33(4):315\u2013325","journal-title":"CNS Drugs"},{"issue":"11","key":"9825_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A (2017) Cerliponase alfa: first global approval. Drugs 77(11):1247\u20131249","journal-title":"Drugs"},{"issue":"11","key":"9825_CR12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/jnr.23423","volume":"92","author":"ML Katz","year":"2014","unstructured":"Katz ML et al (2014) Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J Neurosci Res 92(11):1591\u20131598","journal-title":"J Neurosci Res"},{"issue":"7","key":"9825_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1601-183X.2011.00718.x","volume":"10","author":"DN Sanders","year":"2011","unstructured":"Sanders DN et al (2011) A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis. Genes Brain Behav 10(7):798\u2013804","journal-title":"Genes Brain Behav"},{"key":"9825_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clim.2018.09.003","volume":"197","author":"A Cherukuri","year":"2018","unstructured":"Cherukuri A et al (2018) Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: results from a phase 1\/2 study. Clin Immunol 197:68\u201376","journal-title":"Clin Immunol"},{"issue":"1","key":"9825_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.taap.2014.03.005","volume":"277","author":"BR Vuillemenot","year":"2014","unstructured":"Vuillemenot BR et al (2014) Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution. Toxicol Appl Pharmacol 277(1):49\u201357","journal-title":"Toxicol Appl Pharmacol"},{"key":"9825_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.exer.2016.03.023","volume":"146","author":"RE Whiting","year":"2016","unstructured":"Whiting RE et al (2016) Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease. Exp Eye Res 146:276\u2013282","journal-title":"Exp Eye Res"},{"issue":"20","key":"9825_CR17","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A et al (2018) Study of intraventricular cerliponase Alfa for CLN2 disease. N Engl J Med 378(20):1898\u20131907","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9825_CR18","first-page":"682","volume":"13","author":"A Kohlschutter","year":"2016","unstructured":"Kohlschutter A, Schulz A (2016) CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis). Pediatr Endocrinol Rev 13(Suppl 1):682\u2013688","journal-title":"Pediatr Endocrinol Rev"},{"key":"9825_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/TCRM.S241048","volume":"16","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Trivisano M (2020) Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag 16:213\u2013222","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"9825_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00701-017-3454-z","volume":"160","author":"JC Lau","year":"2018","unstructured":"Lau JC et al (2018) Image-guided Ommaya reservoir insertion for intraventricular chemotherapy: a retrospective series. Acta Neurochir (Wien) 160(3):539\u2013544","journal-title":"Acta Neurochir (Wien)"},{"key":"9825_CR21","doi-asserted-by":"publisher","first-page":"e723","DOI":"10.1016\/j.wneu.2018.10.127","volume":"122","author":"A Wang","year":"2019","unstructured":"Wang A et al (2019) Placement of ommaya reservoirs using electromagnetic neuronavigation and neuroendoscopy: a retrospective study with cost-benefit analysis. World Neurosurg 122:e723\u2013e728","journal-title":"World Neurosurg"},{"issue":"4","key":"9825_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF00152761","volume":"71","author":"AB Fulton","year":"1989","unstructured":"Fulton AB, Hartmann EE, Hansen RM (1989) Electrophysiologic testing techniques for children. Doc Ophthalmol 71(4):341\u2013354","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"9825_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10633-004-1751-3","volume":"109","author":"K Bradshaw","year":"2004","unstructured":"Bradshaw K, Hansen R, Fulton A (2004) Comparison of ERGs recorded with skin and corneal-contact electrodes in normal children and adults. Doc Ophthalmol 109(1):43\u201355","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"9825_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10633-016-9554-x","volume":"133","author":"R Hamilton","year":"2016","unstructured":"Hamilton R, Graham K (2016) Effect of shorter dark adaptation on ISCEV standard DA 0.01 and DA 3 skin ERGs in healthy adults. Doc Ophthalmol 133(1):11\u20139","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"9825_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10633-020-09751-6","volume":"141","author":"M Bach","year":"2020","unstructured":"Bach M, Meroni C, Heinrich SP (2020) ERG shrinks by 10% when reducing dark adaptation time to 10 min, but only for weak flashes. Doc Ophthalmol 141(1):57\u201364","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"9825_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","volume":"133","author":"JV Odom","year":"2016","unstructured":"Odom JV et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133(1):1\u20139","journal-title":"Doc Ophthalmol"},{"issue":"Pt 3b","key":"9825_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/eye.1998.148","volume":"12","author":"RG Weleber","year":"1998","unstructured":"Weleber RG (1998) The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Eye (Lond) 12(Pt 3b):580\u2013590","journal-title":"Eye (Lond)"},{"issue":"4","key":"9825_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5935\/0004-2749.20170053","volume":"80","author":"E Quagliato","year":"2017","unstructured":"Quagliato E et al (2017) Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype. Arq Bras Oftalmol 80(4):215\u2013219","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"9825_CR29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/dmcn.14346","volume":"62","author":"B Dozieres-Puyravel","year":"2020","unstructured":"Dozieres-Puyravel B et al (2020) Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol 62(4):528\u2013530","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"9825_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1350-9462(01)00006-4","volume":"20","author":"S Mohand-Said","year":"2001","unstructured":"Mohand-Said S et al (2001) Rod-cone interactions: developmental and clinical significance. Prog Retin Eye Res 20(4):451\u2013467","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"9825_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/mt.2009.28","volume":"17","author":"Y Yang","year":"2009","unstructured":"Yang Y et al (2009) Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther 17(5):787\u2013795","journal-title":"Mol Ther"},{"issue":"8\u20139","key":"9825_CR32","first-page":"441","volume":"13","author":"JF Le Gargasson","year":"1990","unstructured":"Le Gargasson JF et al (1990) Visual electrophysiology in 101 children with encephalopathy. J Fr Ophtalmol 13(8\u20139):441\u2013448","journal-title":"J Fr Ophtalmol"},{"issue":"8","key":"9825_CR33","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/epi.13820","volume":"58","author":"N Specchio","year":"2017","unstructured":"Specchio N et al (2017) Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia 58(8):1380\u20131388","journal-title":"Epilepsia"},{"key":"9825_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.exer.2014.06.008","volume":"125","author":"RE Whiting","year":"2014","unstructured":"Whiting RE et al (2014) Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Exp Eye Res 125:164\u2013172","journal-title":"Exp Eye Res"},{"key":"9825_CR35","first-page":"2518","volume":"14","author":"FM Mowat","year":"2008","unstructured":"Mowat FM et al (2008) Topographical characterization of cone photoreceptors and the area centralis of the canine retina. Mol Vis 14:2518\u20132527","journal-title":"Mol Vis"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-021-09825-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10633-021-09825-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-021-09825-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T09:08:20Z","timestamp":1625735300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10633-021-09825-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["9825"],"URL":"https:\/\/doi.org\/10.1007\/s10633-021-09825-z","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the welfare of animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}